Amneal Pharmaceuticals stock hits 52-week high at $9.79

Amneal Pharmaceuticals Inc Class A stock reached a significant milestone, hitting a 52-week high at $9.79. According to InvestingPro data, the company’s strong momentum is reflected in its impressive 21.46% year-to-date return and robust market capitalization of $3.06 billion. This achievement underscores a positive trajectory for the company, marking a 15.31% increase over the past year. The stock’s performance reflects strong investor confidence and market optimism in Amneal Pharmaceuticals, as it continues to navigate the competitive pharmaceutical industry. With revenue growth of 9.81% and analyst price targets ranging from $11 to $13, the company’s outlook appears promising. This 52-week high highlights the company’s growth potential and its ability to deliver value to shareholders amidst a fluctuating market landscape. For deeper insights into Amneal’s financial health and growth prospects, access the comprehensive Pro Research Report available on InvestingPro.

In other recent news, Amneal Pharmaceuticals reported its Q2 2025 earnings, showcasing a strong performance with earnings per share (EPS) of $0.25, which exceeded the forecasted $0.17. This represented a 47.06% surprise for investors. However, the company’s revenue slightly missed expectations, totaling $725 million against the anticipated $748.18 million. Additionally, the U.S. Food and Drug Administration approved Amneal’s risperidone extended-release injectable suspension, a generic version of Janssen’s Risperdal Consta, for the treatment of schizophrenia and maintenance therapy for Bipolar I disorder. This approval covers doses of 12.5 mg, 25 mg, 37.5 mg, and 50 mg. These developments highlight significant advancements and challenges for Amneal Pharmaceuticals.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.